Subgroup analyses of the phase 3 CAIRO3 trial: Association of number and total volume of metastases on survival in patients with metastatic colorectal cancer based on a deep-learning automatic segmentation model.

被引：1
|
作者：
Zwart, Koen
Zeeuw, Michiel J.
Stehouwer, Bertine L.
Al-Toma, Dania
Kurk, Sophie
Braat, Manon N. G. J. A.
de Jong, Pim A.
Lagendijk, Jan J. W.
May, Anne M.
Koopman, Miriam
Punt, Cornelis J. A.
Kazemier, Geert
Bol, Guus
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Amsterdam, Dept Surg, Med Ctr, Amsterdam, Netherlands
[3] Univ Med Ctr Utrecht, Dept Radiol, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol, Utrecht, Netherlands
[5] Performat Healthcare Intelligence, Bilthoven, Netherlands
[6] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands
[7] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands
[8] Julius Ctr Hlth Sci & Primary Care, Dept Epidemiol, Utrecht, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
3282-270-434-6184; 613-135-2370-7650-2700; 283-2494-9992; 283-2494-7435; 283-237-2581-242; 283-237-255; 9; 5; 4; 3; 92; 182; 239; 2; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 10 条
  • [1] Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
    Kurk, Sophie A.
    Peeters, Petra H. M.
    Dorresteijn, Bram
    de Jong, Pim A.
    Jourdan, Marion
    Creemers, Geert-Jan M.
    Erdkamp, Frans L. G.
    de Jongh, Felix E.
    Kint, Peter A. M.
    Poppema, Boelo J.
    Radema, Sandra A.
    Simkens, Lieke H. J.
    Tanis, Bea C.
    Tjin-A-Ton, Manuel L. R.
    Van Der Velden, Ankie
    Punt, Cornelis J. A.
    Koopman, Miriam
    May, Anne M.
    CANCER MEDICINE, 2020, 9 (03): : 1033 - 1043
  • [2] Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study
    Goey, K. K. H.
    Elias, S. G.
    van Tinteren, H.
    Lacle, M. M.
    Willems, S. M.
    Offerhaus, G. J. A.
    de Leng, W. W. J.
    Strengman, E.
    ten Tije, A. J.
    Creemers, G. -J. M.
    van der Velden, A.
    de Jongh, F. E.
    Erdkamp, F. L. G.
    Tanis, B. C.
    Punt, C. J. A.
    Koopman, M.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2128 - 2134
  • [3] Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC)
    Koopman, Miriam
    Simkens, Lieke
    May, Anne
    Mol, Linda
    van Tinteren, Harm
    Punt, Cornelis J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [4] Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine plus bevacizumab versus observation after induction treatment with chemotherapy plus bevacizumab in metastatic colorectal cancer (mCRC).
    Koopman, Miriam
    Simkens, Lieke
    May, Anne Maria
    Mol, Linda
    van Tinteren, Harm
    Punt, Cornelis J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306
    Froelich, Matthias F.
    Petersen, Elina L.
    Heinemann, Volker
    Noerenberg, Dominik
    Hesse, Nina
    Gesenhues, Alena B.
    Modest, Dominik P.
    Sommer, Wieland H.
    Hofmann, Felix O.
    Stintzing, Sebastian
    Holch, Julian W.
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 291 - +
  • [6] Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
    Grothey, A.
    Falcone, A.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Adenis, A.
    Tabernero, J.
    Yoshino, T.
    Lenz, H-J.
    Goldberg, R. M.
    Huang, L.
    Wagner, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) > 4 months (m)
    Garcia-Carbonero, R.
    Van Cutsem, E.
    Ciardiello, F.
    Ychou, M.
    Seitz, J-F.
    Hofheinz, R. D.
    Arriaga, Y.
    Verma, U.
    Grothey, A.
    Miriyala, A.
    Kalmus, J.
    Kappeler, C.
    Falcone, A.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
    Salvatore, L.
    Ciardiello, F.
    Cascinu, S.
    Sobrero, A.
    Banzi, C.
    Barone, C.
    Gelsomino, F.
    Maiello, E.
    Siena, S.
    Bergamo, F.
    Carteni, G.
    Di Costanzo, F.
    Di Bartolomeo, M.
    Rimassa, L.
    Russo, A.
    Moscovici, M.
    Van Cutsem, E.
    Grothey, A.
    Zaniboni, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Lupi, Cristiana
    Sensi, Elisa
    Lonardi, Sara
    Mezi, Silvia
    Tomasello, Gianluca
    Ronzoni, Monica
    Zaniboni, Alberto
    Tonini, Giuseppe
    Carlomagno, Chiara
    Allegrini, Giacomo
    Chiara, Silvana
    D'Amico, Mauro
    Granetto, Cristina
    Cazzaniga, Marina
    Boni, Luca
    Fontanini, Gabriella
    Falcone, Alfredo
    LANCET ONCOLOGY, 2015, 16 (13): : 1306 - 1315
  • [10] Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
    Saad, Fred
    Hussain, Maha H. A.
    Tombal, Bertrand
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Nordquist, Luke T.
    Bogmann, Martin
    Tutrone, Ronald
    Shore, Neal D.
    Belkoff, Laurence
    Fralich, Todd
    Jhaveri, Jay
    Srinivasan, Shankar
    Li, Rui
    Verholen, Frank
    Kuss, Iris
    Smith, Matthew R.
    EUROPEAN UROLOGY, 2024, 86 (04) : 329 - 339
1